Michael Nientse Chang

Title: Michael Nientse Chang: Pioneering Antibody Drug Conjugates in Cancer Therapy

Introduction: Michael Nientse Chang is an innovative inventor based in Taipei, Taiwan. With a focus on biotechnology and pharmaceuticals, he has made significant contributions to the field of cancer treatment through his research and inventions.

Latest Patents: Michael Chang holds a patent for "Conjugated biological molecules, pharmaceutical compositions and methods" related to antibody drug conjugates (ADCs). This invention features a drug conjugated to antibody or antigen-binding fragments that target the Globo series antigen. The methods of use described in the patent primarily address cancer therapies and diagnostics, offering potential solutions for various carcinomas, including but not limited to sarcoma, lung cancer, breast cancer, and prostate cancer.

Career Highlights: As an inventor, Michael has dedicated his career to advancing pharmaceutical technologies. His work at Obi Pharma Inc. has positioned him at the forefront of innovative cancer therapies, where he leverages his expertise to develop cutting-edge medical solutions.

Collaborations: Throughout his career, Michael has collaborated with notable colleagues such as Jiann-Shiun Lai and Wan-Fen Li. These collaborations have enhanced his research and contributed to the successful development of his patented technologies.

Conclusion: Michael Nientse Chang continues to be a significant figure in the field of cancer research and therapeutics. His dedication to innovation and collaboration reflects his commitment to improving patient outcomes through cutting-edge scientific advancements.